FDA-cleared medical AI rarely tested for real-world benefits

A new analysis of 1,357 artificial intelligence–based medical devices authorized by the U.S. Food and Drug Administration found that only three had been evaluated for whether they actually improve patient outcomes. Researchers report that most tools were cleared without robust evidence on patient-centered measures such as mortality, strokes, hospitalizations, or quality of life, raising concerns about how clinical AI is validated before widespread deployment.